총 77건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B HIV Infection|Hepatitis B Biological: HEPLISAV-B|Biological: ENGERIX-B National Institute of Allergy and Infectious Diseases (NIAID)|Dynavax Technologies Corporation Phase 3 2020-08-07
2 Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% Non-Small Cell Lung Cancer (NSCLC) Drug: Capmatinib|Biological: Pembrolizumab Novartis Pharmaceuticals|Novartis Phase 2 2020-01-22
3 Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults Rabies (Healthy Volunteers) Biological: Purified vero rabies vaccine - serum free VRVg-2|Biological: Purified inactivated rabies vaccine (Verorab)|Biological: Purified inactivated rabies vaccine (Imovax rabies) Sanofi Pasteur, a Sanofi Company|Sanofi Phase 3 2020-01-02
4 A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation Carcinoma, Hepatocellular Drug: Atezolizumab|Drug: Bevacizumab Hoffmann-La Roche Phase 3 2019-12-31
5 Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) Nasal Polyposis Biological: Benralizumab 30 mg|Biological: Matched placebo AstraZeneca Phase 3 2019-11-25
6 Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) Pneumococcal Infections Biological: V114|Biological: Prevnar 13™|Biological: Pneumovax™23 Merck Sharp & Dohme Corp. Phase 3 2019-11-05
7 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients Migraine Biological: Erenumab|Other: Placebo Novartis Pharmaceuticals|Novartis Phase 3 2019-08-26
8 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) Urinary Bladder Cancer, Muscle-invasive Drug: Pembrolizumab|Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Drug: Enfortumab Vedotin Merck Sharp & Dohme Corp.|Seattle Genetics, Inc.|Astellas Pharma Global Development, Inc. Phase 3 2019-07-24
9 A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed HIV Drug: Rilpivirine|Drug: ARV Background Regimen Janssen Research & Development, LLC Phase 2 2019-07-18
10 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (V114-024) Pneumococcal Infections Biological: V114|Biological: Prevnar 13 Merck Sharp & Dohme Corp. Phase 3 2019-06-25